The trial is intended to evaluate the safety of cardiac radioablation compared with catheter ablation for patients with high-risk, refractory ventricular tachycardia (VT); the treatment was delivered with Varian's cardiac radioablation system, which received breakthrough device designation from the U.S. Food and Drug Administration in May 2021.